Compare RKDA & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | CANF |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | Israel |
| Employees | 9 | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.9M |
| IPO Year | 2015 | N/A |
| Metric | RKDA | CANF |
|---|---|---|
| Price | $2.13 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 23.2K | ★ 532.6K |
| Earning Date | 11-07-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,173,000.00 | $560,000.00 |
| Revenue This Year | $21.31 | $461.72 |
| Revenue Next Year | $28.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.31 | N/A |
| 52 Week Low | $1.76 | $3.36 |
| 52 Week High | $6.71 | $46.60 |
| Indicator | RKDA | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 26.43 | 88.71 |
| Support Level | $1.76 | $0.17 |
| Resistance Level | $3.50 | $4.59 |
| Average True Range (ATR) | 0.31 | 0.11 |
| MACD | -0.14 | 0.39 |
| Stochastic Oscillator | 12.25 | 85.51 |
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, and others.
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).